Psoriatic Arthritis Market, [By Disease Condition (Mild Psoriatic Arthritis, Severe Psoriatic Arthritis, Moderate Psoriatic Arthritis); By Mechanism Type (PDE 4 Inhibitors, Interleukin Blockers, TNF Inhibitors, Others); By End Use (Drug Store, Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)]; and Geography - Trend, Analysis and Forecast till 2025

Report Summary

The Global Psoriatic Arthritis Market Size is expected to gain traction due to the rising need for treating psoriatic arthritis. Also, changing lifestyle results in the growth of population suffering from psoriatic arthritis.

Psoriatic arthritis is majorly found in the individuals suffering from psoriasis which accounts for approximately 30% of population suffering from psoriatic arthritis. Also, it can be termed as irritating, unpredictable baffling skin disease. Psoriasis majorly occurs in the knee, elbows, scalp, torso, palms and soles of the feet. It is an auto-immune disorder which results into the inflammation which triggers joint pains, stiffness, and swelling. Psoriatic arthritis can be characterised by the symptoms such as lower back pain, swollen joints, foot pain, nail pitting, fatigue, and reduced range of motion. Psoriatic arthritis also causes inflammation in spine known as spondyloarthropathies. Psoriatic arthritis is commonly treated with various combination of anti-inflammatory medication (NSAIDs).

Psoriasis influences psoriatic arthritis, which leads to swelling in the joints. According to National Psoriasis Foundation about 10% to 30% of people suffering from psoriasis suffer from psoriatic. The cause of psoriasis is unknown, but some factors such as genetics, change in lifestyle, psoriasis and medication. On the other hand, small percentage of people suffering from psoriatic arthritis may develop mutilan arthritis that leads to severe pain and disabling. In arthritis mutilan the small bones of the body are disabled leading to permanent deformity and disability in an individual.

Continuous technological advancement for developing novel treatment for psoriatic arthritis, to cater the unmet need for treatment of psoriatic arthritis, and changing lifestyle of population will support the growth of global psoriasis drug market.

The global psoriatic arthritis market is primarily driven by growing number of patients from all age group suffering from psoriasis. Additionally, increased consumption of alcohol and changing lifestyle of individuals, increasing incidences of smoking, and rising demand for improved healthcare would also grow the psoriasis drugs market.  

While, increasing number of clinical trials for developing new combination drugs along with the strong, and growing R&D funding and investments on healthcare by the governments of developing and developed economies, unhealthy living, excess consumption of fats and unmet needs for effective treatments influence the market growth during the forecast period. 

However, no proper cure for psoriasis, and side effects caused due to the medical treatment to hinder the growth of psoriatic arthritis market in the near future.

Global Psoriatic Arthritis Market Taxonomy

The global market is segmented on the basis of disease condition, mechanism type, end use and geography

On the basis of disease condition, market is segmented into:

• Mild Psoriatic Arthritis
• Severe Psoriatic Arthritis
• Moderate Psoriatic Arthritis

On the basis of mechanism type, market is segmented into:

• PDE 4 Inhibitors
• Interleukin Blockers
• TNF Inhibitors
• Others

On the basis of end use type, market is segmented into:

• Drug Store
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Geographically, the global market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

High standards of TNF inhibitors that leads the its increasing preference in the U.S., and increasing number of patients suffering from psoriasis to lead the psoriatic arthritis market in North America.

North America is expected to dominate this market over the forecast period. North America holds major share owning to the continuous technological developments by the increasing R&D investments by the major players and government, and increasing number of key players invest in this region. Also, increasing number of patients suffering from psoriasis in the U.S. would spur the market of North America. While, increasing awareness for the use of combination NSAIDs would also spur the psoriatic arthritis market in North America.

However, Asia Pacific psoriatic arthritis market is observed to grow at a faster rate owing to the developing healthcare infrastructure, and rising need for treating the growing number of patients suffering from psoriatic arthritis.

Key players in the global psoriatic arthritis market are:

• Amgen Inc.
• AbbVie Inc.
• Johnson & Johnson Inc.
• Novartis AG
• Eli Lily and Company
• AstraZenca plc
• Celgene Corporation
• Sun Pharma
• Boehringer Ingelheim
• Jansenn Global Services
• Hoffmann-La Roche AG
• Bristol-Myers Squibb Company.